China Biologic Products said its subsidiary, Guizhou Taibang Biological Products, has signed a deal with Xinjiang Deyuan Bioengineering to source 500 tons of raw plasma over the next three years, the company said in a news release.
Japan's SymBio will develop and commercialize pain medicine Ionsys in an exclusive licensing deal with the U.S.-based Medicines Co., marking its first product in the Japanese market and a company push to expand abroad.
French drugmaker Servier has outlicensed some early-stage cancer treatments to Horizon Discovery, holding on to the rights to buy them back if they come through in preclinical development.
Specialty pharma OptiNose hopes to use up to $30 million in new financing to get its OPN-375 in combination with its novel breath-powered device through the FDA. But the agency already demonstrated some skepticism around the device last year--it issued a complete response letter to OptiNose partner Avanir because of device errors and required further testing.
Venture-backed Ark Biosciences has successfully completed a Phase I clinical trial of work on anti-respiratory syncytial virus (RSV) candidate AK0529, hitting a key milestone for the respiratory viral infection and viral hepatitis focused company.
GlaxoSmithKline now has rights to develop inhaled therapeutics using Liquidia's PRINT particle engineering technology. The development builds on a drug delivery alliance between the two companies that commenced in 2012.
As part of its so-called Base Plus Plus Plus strategy, specialty pharmaceutical company Perrigo announced that it is licensing Flamel's LiquiTime extended-release suspension to develop products for the U.S. over-the-counter market.
Regeneron is handing off the Asian rights to its in-development musculoskeletal pain treatment for up to $325 million, handing the antibody over to a subsidiary of Japanese giant Mitsubishi.
Illumina is joining forces with China's Amoy Diagnostics to create next-generation sequencing cancer tests for the Chinese clinical market, expanding its footprint in the country while strengthening its commitment to developing innovative technology for the disease.
Xoma has worked a deal to outlicense a cancer antibody to its longtime partners at Novartis. In the deal Xoma will get $37 million in badly needed cash upfront, some relief on $13.5 million in debt and the chance to earn $480 million in milestones, if all goes as planned.